Hospira 3Q 3Q Revenues: $949.3 million (-6%) 3Q Earnings: $71.4 million (-39%) YTD Revenues: $2.9 billion (+4%) YTD Earnings: $296.6 million (-4%) Comments: Specialty Injectable Pharmaceuticals sales, including U.S. sales of Precedex, meropenem, vancomycin and heparin, help offset the temporary discontinuation of U.S. sales of oxaliplatin (due to a litigation settlement) and the decline in Medication Management Systems (-6% to $152.1 million). Specialty Injectables sales were $558...